PolyNovo Taps Bruce Peatey to Lead Global Expansion and Innovation
PolyNovo Limited has appointed Bruce Peatey as its new CEO, bringing extensive international healthcare experience to drive the company’s next growth phase. Peatey’s leadership is expected to accelerate PolyNovo’s expansion into new markets and outpatient care.
- Bruce Peatey appointed CEO effective 1 December 2025
- Peatey brings leadership experience from Dentsply Sirona’s $1.3 billion US business
- Focus on expanding PolyNovo’s outpatient market and international presence
- Employment package includes $600,000 base salary plus performance incentives
- Company acknowledges interim CEO Dr Robyn Elliott’s contributions
Leadership Change at a Pivotal Moment
PolyNovo Limited, an Australian medical technology innovator, has announced the appointment of Bruce Peatey as its new Chief Executive Officer, effective 1 December 2025. Peatey’s arrival marks a significant leadership transition as the company positions itself for accelerated growth and broader market penetration.
Peatey’s background is notable for its breadth and depth in healthcare and medical devices, having managed major markets for Dentsply Sirona, a global dental equipment leader. Most recently, he led the Americas region, overseeing a business that generated over $1.3 billion USD in revenue in fiscal 2024. His prior role managing the Asia Pacific region further underscores his global commercial expertise.
Strategic Growth and Market Expansion
PolyNovo’s Chairman, David Williams, highlighted Peatey’s proven ability to navigate complex distribution strategies, including direct sales and third-party partnerships. This experience is particularly relevant as PolyNovo aims to expand its footprint in the outpatient care market, especially in the US, where Peatey has established relationships with key distributors like Henry Schein.
Peatey’s expertise in regulatory management and product launches is expected to support PolyNovo’s ambitions to enter new regulatory markets and broaden clinical applications of its flagship NovoSorb technology. The company’s ongoing clinical trials, including the Beta Cell Technologies partnership, signal a commitment to innovation and diversification.
Compensation and Leadership Style
The terms of Peatey’s employment include a base salary of AU$600,000 plus superannuation, with a performance-based annual bonus of up to 50% of base salary tied to financial and ESG targets. Additionally, he will receive a one-off grant of Alignment Share Appreciation Rights valued at AU$600,000, vesting over three years.
Peatey’s leadership style, described as authentic and approachable, aligns with PolyNovo’s culture and strategic vision. His return to Australia from international assignments reflects a personal commitment to advancing the company’s mission from its Melbourne headquarters.
Looking Ahead
As PolyNovo transitions from interim leadership under Dr Robyn Elliott, the company is poised to leverage Peatey’s global experience to accelerate growth. Investors and stakeholders will be watching closely to see how this leadership change translates into market expansion, regulatory progress, and sustained innovation in wound care technology.
Bottom Line?
Bruce Peatey’s appointment signals a new chapter for PolyNovo, with global expansion and outpatient market growth firmly in focus.
Questions in the middle?
- How will Peatey’s leadership impact PolyNovo’s regulatory approvals in new markets?
- What specific strategies will PolyNovo employ to penetrate the US outpatient care sector?
- How might Peatey’s international experience influence PolyNovo’s product development pipeline?
